<DOC>
	<DOCNO>NCT03062449</DOCNO>
	<brief_summary>This Phase IIa , randomize , double-blind , placebo control trial . Subjects participation study identify Investigator base Clinical Dementia Rating score complete part standard practice . Patients meet criterion early Alzheimer 's disease consider study participation , Investigator take additional inclusion/exclusion criterion consideration . Up 40 subject enrol . Subjects participate study randomize receive either gummies contain L-Serine placebo gummies , Investigator study staff blind group assignment .</brief_summary>
	<brief_title>Phase IIa L-serine Trial eAD</brief_title>
	<detailed_description>L-serine ( C3H7NO3 ; 105.09 g/mol ; synonym ( S ) -2-amino-3-hydroxypropanoic acid ) naturally-occurring dietary amino acid . It abundant soy product , edible seaweed , sweet potato , egg , meat . Since L-serine produce astrocyte brain , consider non-essential amino acid . L-serine directly involve biosynthesis purine , pyrimidine , amino acid . Serine residues find protein within protein function site phosphorylation . L-serine consider GRAS ( generally recognize safe ) FDA approve normal food additive CFR172.320 . It widely sell dietary supplement . A pilot study L-serine supplementation 14 patient hereditary sensory neuropathy publish , subsequent trial on-going ( ClinicalTrials.gov identifier NCT01733407 ) . The author report adverse effect dose 400mg/kg/day , average American 75.5kg 30 gram , dose propose use study . L-serine administer orally gummies produce GMP compliant facility ( Knechtel , Chicago , IL ) . Each gummy contain 1 g L-serine ( treatment ) package foil packet contain 15 piece take morning even nine month . The placebo gummy contain L-serine , package take manner . In order ass tolerability patient , design 4 week dose ramp-up . We monitor side-effects amino acid balance blood sample early Alzheimer 's Disease patient dose ramp-up period . If patient tolerate full dose gummies , remain study take total 1 package gummies split two time period within day . The ramp-up schedule procedure observe placebo L-serine patient . Patients assessed baseline , 3 month , 6 month , 9 month .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Diagnosis early stage Alzheimer 's disease score ClinicalDementia Rating Scale score 0.5 1.0 within 6 month prior study enrollment . 2 . Participants able provide inform consent . 3 . Participants take NMDA receptor antagonist medication acetylcholinesterase inhibitor medication must stable dose medication least 30 day prior enrol clinical trial . 4 . Participants able consume study gummy chew throughout course clinical trial . 1 . Diagnosis previous history ischemic stroke , astrocytoma , meningioma oligodendroma . 2 . Diagnosis previous history comorbid diagnosis neurodegenerative disease include amyotrophic lateral sclerosis , Parkinson 's disease , Lewy Body Disease , Pick 's Disease , Huntington 's Disease , Progressive Supra Nuclear Palsy . 3 . Undergoing chemotherapy radiation therapy tumor carcinoma . 4 . Diagnosis previous history type I type II diabetes . 5 . Diagnosis previous history psychiatric illness investigator 's opinion would affect subject 's ability successfully participate study . 6 . In Investigator 's opinion , subject would unable successfully participate study reason .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>L-Serine , Alzheimer 's Disease , AD , Memory ,</keyword>
</DOC>